StocksMediumUpdated•Originally published 5 November 2026•Updated 5 November 2026•
1 min read
Niagen Bioscience Reports Q3 Loss, Misses Revenue Estimates
Key Facts
1Niagen Bioscience reported a quarterly loss of $0.01 per share, which was in line with the Zacks Consensus Estimate.
2The company's results declined compared to a year ago when it reported earnings of $0.05 per share.
Niagen Bioscience reported sales of $27.2 million and a net loss of $1.2 million for the third quarter ending September 2026. The quarterly loss amounted to $0.01 per share, which Zacks reported was in line with analyst consensus estimates but down from the $0.05 per share profit recorded in the prior-year period.
NAGE closed at $2.52 on November 4, 2026, after trading between a session low of $2.4 and a high of $2.59. The financial results mark a year-over-year transition to a net loss alongside a miss on total revenue expectations.